UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Tunnelling anisotropic magnetoresistance due to antiferromagnetic CoO tunnel barriers

Scientific reports, 2015-10, Vol.5 (1), p.15498-15498, Article 15498

2015

Volltextzugriff (PDF)

Docetaxel (Taxotere®) a review of preclinical and clinical experience. Part I: preclinical experience

Anti-cancer drugs, 1995-06, Vol.6 (3), p.339-355

1995

Volltextzugriff (PDF)

Hepatic biotransformation of docetaxel (Taxotere®) in vitro : Involvement of the CYP3A subfamily in humans

Cancer research (Chicago, Ill.), 1996-03, Vol.56 (6), p.1296-1302

1996

Volltextzugriff (PDF)

The pharmacokinetics of idraparinux, a long‐acting indirect factor Xa inhibitor: population pharmacokinetic analysis from Phase III clinical trials

Journal of thrombosis and haemostasis, 2009-04, Vol.7 (4), p.559-565

2009

Volltextzugriff (PDF)

Irinotecan (CPT-11) metabolites in human bile and urine

Clinical cancer research, 1996-12, Vol.2 (12), p.1943-1949

1996

Volltextzugriff (PDF)

Temperature dependence of magnetocurrent in a magnetic tunnel transistor

Journal of applied physics, 2005-11, Vol.98 (10)

2005

Volltextzugriff (PDF)

Involvement of human CYP1A isoenzymes in the metabolism and drug interactions of riluzole in vitro

The Journal of pharmacology and experimental therapeutics, 1997-09, Vol.282 (3), p.1465

1997

Volltextzugriff (PDF)

Pharmacokinetics and metabolism of Taxotere (docetaxel)

Cancer surveys, 1993, Vol.17, p.305

1993

Volltextzugriff (PDF)

Human Aminopeptidases: A Review of the Literature

Clinical chemistry and laboratory medicine, 1988, Vol.26 (12)

1988

Volltextzugriff (PDF)

Alanine aminopeptidase in serum: biological variations and reference limits

Clinical chemistry (Baltimore, Md.), 1988-07, Vol.34 (7), p.1422-1426

1988

Volltextzugriff (PDF)

The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers

Clinical pharmacology and therapeutics, 2002-09, Vol.72 (3), p.308-318

2002

Volltextzugriff (PDF)

Micro-scale two-dimensional electrophoresis of alkaline phosphatase from serum

Clinical chemistry (Baltimore, Md.), 1988-04, Vol.34 (4), p.730-735

1988

Volltextzugriff (PDF)

Clinical significance of a new isoform of serum alanine aminopeptidase; relationship with liver disease and alcohol consumption

Clinica chimica acta, 1989-01, Vol.179 (1), p.23-31

1989

Volltextzugriff (PDF)

Dosage Adjustment and Pharmacokinetic Profile of Irinotecan in Cancer Patients With Hepatic Dysfunction

Journal of clinical oncology, 2002-11, Vol.20 (21), p.4303-4312

2002

Volltextzugriff (PDF)

Human aminopeptidases: a review of the literature

Journal of clinical chemistry and clinical biochemistry, 1988-12, Vol.26 (12), p.795

1988

Volltextzugriff (PDF)

Population pharmacokinetics and pharmacodynamics of enoxaparin in unstable angina and non‐ST‐segment elevation myocardial infarction

British journal of clinical pharmacology, 2003-10, Vol.56 (4), p.407-414

2003

Volltextzugriff (PDF)

Temperature dependence of magnetocurrent in a magnetictunnel transistor

Journal of applied physics, 2005-11, Vol.98 (10), p.103701-103701-4

2005

Volltextzugriff (PDF)

Phase I Pharmacokinetic, Food Effect, and Pharmacogenetic Study of Oral Irinotecan Given as Semisolid Matrix Capsules in Patients with Solid Tumors

Clinical cancer research, 2005-02, Vol.11 (4), p.1504-1511

2005

Volltextzugriff (PDF)

Phase I and Pharmacokinetic Study of Oral Irinotecan Given Once Daily for 5 Days Every 3 Weeks in Combination With Capecitabine in Patients With Solid Tumors

Journal of clinical oncology, 2005-02, Vol.23 (4), p.889-898

2005

Volltextzugriff (PDF)

Quantitative measurement of plasma hemoglobin by second derivative spectrophotometry

Clinica chimica acta, 1985-02, Vol.146 (1), p.65-73

1985

Volltextzugriff (PDF)

Phase I study of an oral formulation of irinotecan administered daily for 14 days every 3 weeks in patients with advanced solid tumours

Cancer chemotherapy and pharmacology, 2005-03, Vol.55 (3), p.263-270

2005

Volltextzugriff (PDF)

Tunneling anisotropic magnetoresistance in C 60 -based organic spintronic systems

Physical review. B, Condensed matter and materials physics, 2014-05, Vol.89 (17), Article 174419

2014

Volltextzugriff (PDF)

Tunneling anisotropic magnetoresistance in C sub(60) -based organic spintronic systems

Physical review. B, Condensed matter and materials physics, 2014-05, Vol.89 (17)

2014

Volltextzugriff (PDF)

Tunneling anisotropic magnetoresistance in Co/AlO sub(x)/Al tunnel junctions with fcc Co (111) electrodes

Physical review. B, Condensed matter and materials physics, 2013-08, Vol.88 (5)

2013

Volltextzugriff (PDF)

Tunneling anisotropic magnetoresistance in Co/AlO x /Al tunnel junctions with fcc Co (111) electrodes

Physical review. B, Condensed matter and materials physics, 2013-08, Vol.88 (5), Article 054407

2013

Volltextzugriff (PDF)

1 – 25 von 34

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(25)
Mit Volltextzugriff
(20)

Publikationsform

Artikel
(34)

Sprache

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Tunnelling anisotropic magnetoresistance due to antiferromagnetic CoO tunnel barriers

Docetaxel (Taxotere®) a review of preclinical and clinical experience. Part I: preclinical experience

Hepatic biotransformation of docetaxel (Taxotere®) in vitro : Involvement of the CYP3A subfamily in humans

The pharmacokinetics of idraparinux, a long‐acting indirect factor Xa inhibitor: population pharmacokinetic analysis from Phase III clinical trials

Irinotecan (CPT-11) metabolites in human bile and urine

Temperature dependence of magnetocurrent in a magnetic tunnel transistor

Involvement of human CYP1A isoenzymes in the metabolism and drug interactions of riluzole in vitro

Pharmacokinetics and metabolism of Taxotere (docetaxel)

Human Aminopeptidases: A Review of the Literature

Alanine aminopeptidase in serum: biological variations and reference limits

The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers

Micro-scale two-dimensional electrophoresis of alkaline phosphatase from serum

Clinical significance of a new isoform of serum alanine aminopeptidase; relationship with liver disease and alcohol consumption

Dosage Adjustment and Pharmacokinetic Profile of Irinotecan in Cancer Patients With Hepatic Dysfunction

Human aminopeptidases: a review of the literature

Population pharmacokinetics and pharmacodynamics of enoxaparin in unstable angina and non‐ST‐segment elevation myocardial infarction

Temperature dependence of magnetocurrent in a magnetictunnel transistor

Phase I Pharmacokinetic, Food Effect, and Pharmacogenetic Study of Oral Irinotecan Given as Semisolid Matrix Capsules in Patients with Solid Tumors

Phase I and Pharmacokinetic Study of Oral Irinotecan Given Once Daily for 5 Days Every 3 Weeks in Combination With Capecitabine in Patients With Solid Tumors

Quantitative measurement of plasma hemoglobin by second derivative spectrophotometry

Phase I study of an oral formulation of irinotecan administered daily for 14 days every 3 weeks in patients with advanced solid tumours

Tunneling anisotropic magnetoresistance in C 60 -based organic spintronic systems

Tunneling anisotropic magnetoresistance in C sub(60) -based organic spintronic systems

Tunneling anisotropic magnetoresistance in Co/AlO sub(x)/Al tunnel junctions with fcc Co (111) electrodes

Tunneling anisotropic magnetoresistance in Co/AlO x /Al tunnel junctions with fcc Co (111) electrodes

Suchergebnisse filtern